You have 9 free searches left this month | for more free features.

Previously untreated MDS

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

High Grade MDS Trial in Aurora (Omacetaxine, Azacitidine)

Recruiting
  • High Grade Myelodysplastic Syndromes
  • Aurora, Colorado
    Universtiy of Colorado Denver
Nov 17, 2022

MDS Trial (Decitabine/Cedazuridine, Magrolimab)

Not yet recruiting
  • Myelodysplastic Syndromes
  • (no location specified)
Apr 18, 2023

Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes Trial in La Jolla,

Recruiting
  • Acute Myelogenous Leukemia (AML) Due to Therapy
  • Acute Myeloid Leukemia With Myelodysplasia-Related Changes
  • Orange, California
  • +2 more
Nov 30, 2022

Untreated Myelodysplastic Syndrome Trial in France (Onureg + Venetoclax)

Not yet recruiting
  • Untreated Myelodysplastic Syndrome
  • Onureg + Venetoclax
  • Angers, France
  • +9 more
Mar 13, 2023

MDS Over Time - Comparison of Treated vs Untreated Patients

Completed
  • Myelodysplastic Syndromes
    • Vienna, Austria
      Hanusch Krankenhaus, 3.Medizinische Abteilung
    Nov 21, 2022

    Uveal Melanoma Trial in Pittsburgh (Tebentafusp)

    Not yet recruiting
    • Uveal Melanoma
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Oct 5, 2023

    Follicular Lymphoma, Tumor Trial in Houston (Obinutuzumab, CC-99282)

    Not yet recruiting
    • Follicular Lymphoma
    • Tumor
    • Houston, Texas
      M D Anderson Cancer Center
    Oct 30, 2023

    Obinutuzumab-based Therapy for Previously Untreated FL

    Recruiting
    • Follicular Lymphoma
    • Shanghai, Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    Jun 3, 2023

    Untreated Advanced NSCLC Trial in Fuzhou (Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and

    Recruiting
    • Untreated Advanced Non-small Cell Lung Cancer
    • Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy
    • Fuzhou, Fujian, China
      Fujian Cancer Hospital
    Nov 13, 2023

    Peripheral T-cell Lymphoma Trial (Linperlisib in combination with CHOP)

    Not yet recruiting
    • Peripheral T-cell Lymphoma
    • Linperlisib in combination with CHOP
    • (no location specified)
    Jul 10, 2023

    Mantle Cell Lymphoma Trial (Acalabrutinib, Rituximab)

    Not yet recruiting
    • Mantle Cell Lymphoma
    • (no location specified)
    Oct 31, 2022

    Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1

    Not yet recruiting
    • Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
    • Ivosidenib 500mg
    • Placebo
    • (no location specified)
    Nov 7, 2023

    Untreated Advanced or Recurrent Thymic Carcinomas Trial in Chuo (MK-3475, Lenvatinib, Carboplatin)

    Not yet recruiting
    • Untreated Advanced or Recurrent Thymic Carcinomas
    • Chuo, Tokyo, Japan
      National Cancer Center Hospital
    Apr 16, 2023

    Peripheral T Cell Lymphoma, Epigenetic Repression Trial in Tianjin (Chidamide, Azacitidine)

    Recruiting
    • Peripheral T Cell Lymphoma
    • Epigenetic Repression
    • Tianjin, Tianjin, China
      Institute of Hematology & Blood Diseases Hospital
    Jul 14, 2023

    Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance

    Not yet recruiting
    • Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)
      • (no location specified)
      Dec 16, 2022

      Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma Trial (Ibrutinib, Venetoclax)

      Not yet recruiting
      • Leukemia, Lymphocytic, Chronic, B-Cell
      • Small Lymphocytic Lymphoma
      • (no location specified)
      Jul 19, 2023

      Acute Myeloid Leukemia Trial in Tianjin (Mitoxantrone HCl liposome injection, Cytarabine, Homoharringtonine)

      Not yet recruiting
      • Acute Myeloid Leukemia
      • Mitoxantrone hydrochloride liposome injection
      • +3 more
      • (no location specified)
      May 29, 2023

      Large B-Cell Lymphoma Trial in Xi'an (Glofitamab, Polatuzumab vedotin, Rituximab)

      Not yet recruiting
      • Large B-Cell Lymphoma
      • Xi'an, China
        First Affiliated Hospital of Medical College of Xi'an Jiaotong U
      Sep 14, 2023

      Breast Cancer Trial (RO7247669, Pembrolizumab, Nab-Paclitaxel)

      Not yet recruiting
      • Breast Cancer
      • (no location specified)
      May 2, 2023

      Acute Myeloid Leukemia Trial in Tianjin (Mitoxantrone HCl liposome injection, Cytarabine, Homoharringtonine)

      Not yet recruiting
      • Acute Myeloid Leukemia
      • Mitoxantrone hydrochloride liposome injection
      • +3 more
      • Tianjin, China
        Institute of Hematology & Blood Diseases Hospital
      Jul 1, 2023

      Previously Untreated Peripheral T-cell Lymphoma Trial in Tampa, Saint Louis, New York (CC-486 Administration, CHOP

      Active, not recruiting
      • Previously Untreated Peripheral T-cell Lymphoma
      • CC-486 Administration
      • CHOP Administration
      • Tampa, Florida
      • +3 more
      Jan 18, 2023

      Urothelial Carcinoma Trial (disitamab vedotin, pembrolizumab, gemcitabine)

      Not yet recruiting
      • Urothelial Carcinoma
      • disitamab vedotin
      • +4 more
      • (no location specified)
      Jun 9, 2023

      NSCLC Stage IV Trial in New York (Pembrolizumab, Radiation, Chemotherapy)

      Recruiting
      • NSCLC Stage IV
      • New York, New York
        NYU Langone Health
      Jan 11, 2023

      Chronic Lymphocytic Leukemia Trial (Acalabrutinib, Obinutuzumab)

      Not yet recruiting
      • Chronic Lymphocytic Leukemia
      • (no location specified)
      Jul 10, 2023